Journal Information

On this page: Aims & Scope Subject Categories | Journal metrics | Indexing | Newsfeeds | Journal details | Submissions video

Aims and Scope

The British Journal of Cancer (BJC) is one of the most cited general cancer journals, it is committed to publishing cutting edge discovery, translational and clinical cancer research. The BJC aims to provide a global platform to disseminate important research within the broad spectrum of oncology. The journal welcomes research across all cancer types and has a focus on: metastasis, microenvironment, immunology and immunotherapy, targeted and next-generation therapeutics, chemotherapy and radiotherapy, mechanisms of resistance, clinical trials, genomics, epigenomics and precision medicine, epidemiology, metabolism and state-of-the art diagnostic approaches.

The BJC is published in association with Cancer Research UK, the world’s leading independent cancer charity dedicated to saving lives through research.

Submit your next manuscript to BJC and benefit from:

  • International and highly respected editorial team
  • Rapid decision and publication times
  • High exposure and article visibility via
  • Funder-compliant open access options available
  • Engaged and growing Twitter following at @BrJCancer
  • Share your article through SharedIt: Springer Nature’s content-sharing initiative allowing authors and subscribers to share links to view-only, full-text articles from this journal

Subject Categories

BJC publishes across the following six subject categories:

  • Clinical Studies
  • Translational Therapeutics
  • Molecular Diagnostics
  • Genetics and Genomics
  • Cellular and Molecular Biology
  • Epidemiology

Translational Therapeutics
Translational Therapeutics is dedicated to scientific work that has possible direct applicability in clinical uses or opens new avenues for treatments. The type of manuscript ranges from basic research to early informative clinical trials with extensive concomitant biomaterial analyses. Translational concepts include new computational or wet lab Technologies as well.

Molecular Diagnostics
The Molecular Diagnostic subject category considers studies that examine genomic, transcriptomic, epigenomic, and proteomic biomarkers in the context of cancer diagnosis, staging, prognosis, therapeutic prediction, and radiographic and pathologic characteristics. We are particularly interested in papers that explore novel or evolving biomarkers with direct clinical applicability in cancer care.

Genetics and Genomics
This subject category covers the use of genetic epidemiology and bioinformatics, together with molecular and cell biology, to identify and characterise the genetic and epigenetic factors underlying tumour development and progression. We are interested in papers which focus on the mechanistic consequences of genetic variance, and adequately powered studies of how genetic and epigenetic variation impacts patient risk and outcome phenotypes, in particular where these point to new clinical approaches. Wherever possible, bioinformatics analyses should be supported by experimental results.

Cellular and Molecular Biology
The Cellular and Molecular Biology subject category considers studies that provide novel insight into basic cellular and molecular mechanisms of cancer, but are not biomarker, methodology, or pathology focused. Studies considered for this category will generally go beyond in vitro and/or in silico evaluation of basic cellular and molecular mechanisms of cancer, and usually include the use of appropriate in vivo model systems. Findings of studies considered for this category should be clinically and/or therapeutically applicable.

The Epidemiology subject category focuses on prevention, early detection, and factors that influence the risk and prognosis of cancer.

To explore the type of articles that the BJC publishes, please browse our subject pages.

Journal metrics

Article-level metrics such as number of downloads, citations and online attention provide an overview of the attention received by a paper, and are available from each article page. 

The 2021 peer review performance metrics for the BJC are shown below:

Average time to decision without external review - 6 days
Average time to decision following external review - 53 days
Average time from submission to acceptance - 156 days
Average time from acceptance to publication - 18 days
Article page views - 2,172,504
Altmetric mentions - 9,335

The 2021 journal citation metrics for British Journal of Cancer are as follows:

2-year Impact Factor*: 7.64
5-year Impact Factor*: 7.57
Immediacy index*: 1.884
Eigenfactor® score*: 0.04207
Article influence score*: 2.153
JCR Rank*: ONCOLOGY 39/242
Journal Citation Score*: 1.35

SNIP: 1.737
SJR: 2.833
Usage: 5,211,249 Downloads (in 2021)

*2020 Journal Citation Reports® Science Edition (Clarivate Analytics, 2021). For more information on these journal metrics, please visit this link.

Article-level metrics such as number of downloads, citations and online attention provide an overview of the attention received by a paper, and are available from each article page. 


All articles published in the BJC are included in:

EBSCO Discovery Service
Google Scholar
Science Citation Index
Science Citation Index Expanded (SciSearch)
Current Contents / Clinical Medicine
Current Contents / Life Sciences
Summon by ProQuest
EBSCO Academic Search
PubMed Central
EBSCO Advanced Placement Source
EBSCO Biomedical Reference Collection
INIS Atomindex


The BJC now provides its latest table of contents as an RSS web feed. This allows users with an RSS reader to receive automatic updates whenever new content is added to these pages.

Receive the BJC's current issue table of contents.

Find out more about RSS feeds, how to download an RSS reader and see all the news feeds offered by Springer Nature.

Follow us on Twitter @BrJCancer

Journal details


ISSN: 0007-0920

Submissions video